Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis

Facility-Level Interpatient Hemoglobin Variability in Hemodialysis Centers Participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations With Mortality, Patient Characteristics, and Facility Practices

(2011) Ronald L. Pisoni et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Simplifying anemia management in hemodialysis patients: ESAs administered at longer dosing intervals can enhance opportunities to provide patient-focused care

(2011) Brigitte Schiller et al.   CURRENT MEDICAL RESEARCH AND OPINION

Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis

(2011) Irfan Khan et al.   BMC Nephrology

Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia

(2010) Stefan Krivoshiev et al.   ADVANCES IN THERAPY

Hemoglobin Variability and Mortality: Confounding by Disease Severity

(2010) Eric D. Weinhandl et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Population Pharmacokinetic/Pharmacodynamic Model for C.E.R.A. in Both ESA-Naïve and ESA-Treated Chronic Kidney Disease Patients With Renal Anemia

(2010) Pascal Chanu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hemoglobin Variability Does Not Predict Mortality in European Hemodialysis Patients

(2010) K.-U. Eckardt et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial

(2010) F. Carrera et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Hemoglobin Variability in Chronic Kidney Disease: A Cross-Sectional Study

(2009) David M. Spiegel   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis

(2009) Hiroshi Nagaya et al.   Clinical and Experimental Nephrology

Prevention of vertebral fractures in osteoporosis: mixed treatment comparison of bisphosphonate therapies

(2009) Jeroen P. Jansen et al.   CURRENT MEDICAL RESEARCH AND OPINION

C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study

(2009) Michèle KESSLER et al.   Hemodialysis International

Hemoglobin Variability in Anemia of Chronic Kidney Disease

(2009) K. Kalantar-Zadeh et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Association of Hemoglobin Variability and Mortality among Contemporary Incident Hemodialysis Patients

(2008) S. M. Brunelli et al.   Clinical Journal of the American Society of Nephrology

Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia

(2008) Stefan Krivoshiev et al.   CURRENT MEDICAL RESEARCH AND OPINION

Randomized Study of Darbepoetin Alfa and Recombinant Human Erythropoietin for Treatment of Renal Anemia in Chronic Renal Failure Patients Receiving Peritoneal Dialysis

(2008) Wen-Yi Li et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study

(2008) B. Canaud et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Use of Indirect and Mixed Treatment Comparisons for Technology Assessment

(2008) Alex Sutton et al.   PHARMACOECONOMICS